News

This decision follows Delcath’s meeting with representatives of the FDA, along with the principal investigator at the National Cancer Institute (NCI). Resumption of study accrual follows a voluntary

The new use for the unapproved drug candidate was discovered by Gene Logic’s drug repositioning division. Under its drug repositioning agreement with Pfizer, Gene Logic has been seeking

According to Rosetta, recent studies have revealed key roles of microRNAs as regulators of growth, development, function and responses to stress in the heart. The company said that

The alliance will develop antibodies that bind to amyloid beta, a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in Alzheimer’s patients. Neurimmune will conduct

The company said that it will receive $25 million in gross proceeds from the sale of 4,943,154 shares of its common stock and the issuance of seven-year warrants

The kit, which monitors the viral load of infected patients, is now available to doctors in Canada to help them determine the success of a treatment. The ready-to-use

As part of the license agreement, MorphoSys gains the right to sublicense the patents in conjunction with its proprietary technology. The license agreement provides MorphoSys with flexibility for

The primary objective of Hana’s Phase II study is to assess the efficacy of Marqibo as determined by response rates in patients with uveal melanoma. Secondary objectives are

Exelixis has the option to sell its remaining interest to Taconic, and Taconic also has an option to purchase Exelixis’s remaining interest during certain times and under certain